Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Piracetam and Unifiram — mechanism, side effects, legal status, and pricing.
Piracetam is a non-peptide pyrrolidinone-derivative racetam, the prototypical member of the nootropic racetam class. It is approved in the EU/UK exclusively for adult cortical myoclonus as adjunctive therapy (marketed as Nootropil), but has NO FDA approval in any form in the United States. The FDA has rejected its New Dietary Ingredient notification and issued warning letters to US vendors marketing it as a supplement. Piracetam itself is not WADA-prohibited, though its derivative phenylpiracetam is a banned stimulant.
Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.
Piracetam
Unifiram
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Piracetam
No pricing data yet.
Check Piracetam prices →Unifiram
COA corpus from Disclosed Labs — independently tested batches only.
Piracetam
1
COAs
99.8%
Avg purity
1
Labs
Unifiram
1
COAs
99.4%
Avg purity
1
Labs
Piracetam is an approved prescription drug in the EU/UK for adult cortical myoclonus (adjunctive therapy) and has been studied off-label in multiple placebo-controlled human trials for age-related cognitive decline, post-stroke aphasia, post-ECT cognitive deficit, and post-CABG cognitive decline, with mixed results. A Cochrane systematic review (2001) concluded that available evidence does not support piracetam's use for dementia or cognitive impairment beyond a global-impression measure. In rodent models, piracetam reduced focal ischemia infarct volume by ~35.8%, improved neurological/locomotor outcomes and survival, attenuated oxidative stress and excitatory amino acid release in oxygen-glucose deprivation, and showed anticonvulsant and neuroprotective effects in PTZ-induced epilepsy.
Key references
No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.
Piracetam and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs